With the new Monowave 300 microwave synthesis reactor, Anton Paar enters the prosperous market of compact monomode microwave synthesisers. The smart and powerful instrument is designed to fully meet the needs and requirements of synthesis chemists in pharmaceutical and academic research departments.
CoreLab Partners, Inc, the global entity resulting from the merger between RadPharm and Medifacts International in February of this year, has recently completed the first ever regulatory mandated Thorough QT (TQT) study conducted in the Asia Pacific Rim and the first TQT study for a Japanese new drug application (NDA).
Enabling improved accuracy in drug safety through better toxicology testing.
Somerset House Consultants has recently completed a major project for a US-based contract manufacturer. The company is an established manufacturer of both clinical trial supplies and marketed products for the US market, with a successful FDA inspection record. However, an inspection by European regulatory authorities had found that the company did not comply with EU GMP requirements and could not supply products to Europe.
Exploristics, the innovative analysis group, is pleased to announce that Anaxsys Limited have received the CE Mark for their respiratory rate monitor, respiR8, from the British Standards Institute (BSI).
Version 4.8 of NMRPredict has been released, including many new features.
ARTES Biotechnology announced today the acquirement of the ANAVAX virus-like particle (VLP) technology from Select Vaccines Ltd. ANAVAX is a patent-protected VLP technology that can be applied to the prevention of several infectious diseases.
Please enjoy the September issue of DASGIP Spotlight highlighting three of our latest news on products, applications and business development.
Kemwell has signed an agreement on the ECM product FormPipe Platina to ensure management of the documentation for manufacturing and testing, and support for business processes such as alteration and deviation management.
Scarab Genomics, a pioneer in the world of E. coli genomics and production strains, and Lonza, a world leader in biopharmaceutical development and production, announced today the companies have entered into a preferred marketing and sales agreement for Scarab Genomics’ Clean Genome® E. coli. Financial details of the contract were not disclosed.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.